Auris regains compliance with one Nasdaq listing requirement
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
Switzerland's Auris Medical Holding AG regained compliance with Nasdaq's minimum bid price requirement of $1 per share.
However, the pharmaceuticals company is yet to regain compliance with the stock exchange's minimum $35 million market value of listed securities.
Auris has until July 10 to regain compliance with that condition.